#1 Clinical Trials Search in Europe

Rezpegaldesleukin

Rezpegaldesleukin, also known as REZPEG or NKTR-358, is an innovative drug currently being studied in clinical trials for its potential in treating moderate to severe atopic dermatitis and severe to very severe alopecia areata. These trials aim to evaluate the drug’s efficacy and safety in adult patients, offering new possibilities for those struggling with these challenging skin conditions.

Table of Contents

What is Rezpegaldesleukin?

Rezpegaldesleukin, also known as Rezpeg, NKTR-358, or formerly LY3471851, is a new medication being studied for the treatment of various autoimmune conditions[1][2]. It is a type of drug called a pegylated-recombinant-human interleukin-2, which means it’s a modified version of a naturally occurring protein in our body that helps regulate the immune system.

What Conditions Does Rezpegaldesleukin Treat?

Currently, Rezpegaldesleukin is being investigated for the treatment of two main conditions:

  • Moderate to Severe Atopic Dermatitis: This is a chronic skin condition characterized by itchy, inflamed skin. It’s often referred to as eczema[1].
  • Severe to Very Severe Alopecia Areata: This is an autoimmune disorder that causes hair loss, often in patches[2].

Both of these conditions are autoimmune disorders, where the body’s immune system mistakenly attacks healthy cells.

How Does Rezpegaldesleukin Work?

While the exact mechanism isn’t fully explained in the clinical trial information, Rezpegaldesleukin is designed to help regulate the immune system. As a modified version of interleukin-2, it likely works by influencing certain types of immune cells, potentially helping to reduce the overactive immune response seen in autoimmune conditions[1][2].

How is Rezpegaldesleukin Administered?

Rezpegaldesleukin is administered as a subcutaneous injection. This means it’s injected just under the skin. The frequency of administration varies depending on the specific trial and treatment phase, but it’s typically given every 2 to 4 weeks[1][2].

Current Clinical Trials

Rezpegaldesleukin is currently being studied in Phase 2b clinical trials. These are important studies that help determine the effectiveness and safety of the drug before it can be approved for widespread use. Two notable trials are:

  1. A study for moderate to severe atopic dermatitis in adults, lasting up to 54 weeks[1].
  2. A study for severe to very severe alopecia areata in adults, lasting up to 81 weeks[2].

Both trials are randomized, double-blind, and placebo-controlled, which means participants are randomly assigned to receive either the drug or a placebo, and neither the participants nor the researchers know who is receiving which until the study is complete. This helps ensure the results are as unbiased as possible.

How Effective is Rezpegaldesleukin?

The effectiveness of Rezpegaldesleukin is still being determined through these clinical trials. The studies are measuring several outcomes to assess how well the drug works:

For atopic dermatitis[1]:

  • Changes in the Eczema Area and Severity Index (EASI): This is a tool used to measure the extent and severity of eczema. A reduction in EASI score indicates improvement.
  • Changes in the SCORing Atopic Dermatitis Index (SCORAD): Another measure of eczema severity.
  • Improvement in itching, as measured by a numerical rating scale.

For alopecia areata[2]:

  • Changes in the Severity of Alopecia Tool (SALT) score: This measures the extent of hair loss. A decrease in SALT score indicates hair regrowth.

The results of these trials will help determine how effective Rezpegaldesleukin is in treating these conditions.

Safety and Side Effects

As with any new medication, the safety of Rezpegaldesleukin is being closely monitored in these clinical trials. The studies are tracking the incidence of side effects, including both serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs)[1]. However, specific information about potential side effects is not provided in the trial descriptions.

It’s important to note that Rezpegaldesleukin is still an investigational drug. This means it has not yet been approved by regulatory agencies like the FDA for general use. More research is needed to fully understand its effectiveness and safety profile.

Aspect Atopic Dermatitis Trial Alopecia Areata Trial
Trial Phase Phase 2b Phase 2b
Study Design Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Randomized, Double-Blind, Parallel Group, Placebo-Controlled
Number of Arms 4 (3 dose regimens + placebo) 3 (2 dose levels + placebo)
Primary Outcome Mean percent change in EASI from baseline at Week 16 Percent change from baseline in SALT score at Week 36
Treatment Duration 52 weeks (with follow-up to Week 104) 36 weeks (with optional 16-week extension)
Dosing Frequency Every 2 or 4 weeks (varies by arm) Every 2 weeks
Key Secondary Outcomes vIGA-AD, EASI-75, EASI-90, Itch NRS, SCORAD SALT50/75/90, Absolute SALT score ≤10/20/30/50

FAQ

  • What is Rezpegaldesleukin? Rezpegaldesleukin is a pegylated-recombinant-human interleukin-2 drug being tested for treating atopic dermatitis and alopecia areata. It's administered through subcutaneous injection.
  • What conditions are being studied in these clinical trials? The clinical trials are focusing on moderate to severe atopic dermatitis and severe to very severe alopecia areata in adult patients.
  • How long do these clinical trials last? The atopic dermatitis trial lasts up to 104 weeks (2 years), while the alopecia areata trial has a maximum duration of approximately 81 weeks.
  • What are the main outcomes being measured in these trials? For atopic dermatitis, the primary outcome is the change in the Eczema Area and Severity Index (EASI). For alopecia areata, it's the change in the Severity of Alopecia Tool (SALT) score.
  • Are there any placebo groups in these trials? Yes, both trials include placebo groups to compare the effectiveness of Rezpegaldesleukin against a non-active treatment.

Ongoing Clinical Trials on Rezpegaldesleukin

  • Study on Rezpegaldesleukin for Treating Severe Alopecia Areata in Adults

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Poland

  • Study on Rezpegaldesleukin for Treating Moderate-to-Severe Atopic Dermatitis in Adults

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Croatia Czechia Germany Hungary Poland +1

Glossary

  • Atopic Dermatitis: A chronic inflammatory skin condition characterized by itchy, red, and swollen skin. It's a type of eczema that can significantly impact quality of life.
  • Alopecia Areata: An autoimmune disorder causing hair loss in patches, which can progress to total scalp hair loss (alopecia totalis) or complete body hair loss (alopecia universalis).
  • EASI (Eczema Area and Severity Index): A tool used to measure the extent and severity of atopic dermatitis. Scores range from 0 to 72, with higher scores indicating more severe condition.
  • SALT (Severity of Alopecia Tool): A method to assess the extent of scalp hair loss in alopecia areata. The score ranges from 0 to 100, with higher scores indicating greater hair loss.
  • Rezpegaldesleukin: A pegylated-recombinant-human interleukin-2 drug being studied for its potential in treating autoimmune conditions like atopic dermatitis and alopecia areata.
  • Subcutaneous Injection: A method of administering medication by injecting it into the tissue layer between the skin and the muscle.
  • Placebo: An inactive substance used in clinical trials to compare the effects of a drug against a non-treatment option.
  • vIGA-AD (Validated Investigator Global Assessment for Atopic Dermatitis): A scale used to assess the overall severity of atopic dermatitis, ranging from 0 to 4, with higher scores indicating more severe condition.
  • SCORAD (SCORing Atopic Dermatitis): A clinical tool used to assess the extent and severity of atopic dermatitis. Scores range from 0 to 103, with higher scores indicating more severe condition.

References